Drugs / Shenqi Fuzheng Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07843251 | Oct 2026 → Dec 2030 expected | lacrimal apparatus disorder, non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shenqi Fuzheng Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07843251 ↗ |
| Known as | SFI | “Shenqi Fuzheng Injection (SFI) in combination with anti-PD-1 monoclonal antibody plus platinum-based doublet chemotherapy as neoadjuvant therapy.” NCT07843251 ↗ |
| Route | Intravenous | “given by intravenous infusion” NCT07843251 ↗ |